諾和諾德（Novo Nordisk）：首評買進，呼籲底部已現 (NYSE:NVO)
· seekingalpha.com
諾和諾德的口服型 Wegovy 正在擴大肥胖症治療市場，而非僅僅蠶食注射劑市場。閱讀為何 NVO 股票值得買進。
Lifescience investor focused on non-consensus long-short investment ideas. I focus on small to mid-cap biotechnology companies that are public on the US and EU ...